Articles From: Identiv CEO Jason Hart to Present at CARTES SECURE CONNEXIONS on Establishing Trust in the Connected World to IDEXX Laboratories, Inc. (Nasdaq: IDXX) to Ring The Nasdaq Stock Market Closing Bell


FREMONT, Calif., Nov.
Sign-up for Identiv Joins FIDO Alliance investment picks
FREMONT, Calif., Oct.
Sign-up for Identiv Launches October uTrust Webinar Series investment picks
FREMONT, Calif., Nov.
Sign-up for Identiv Reports Q3 2014 Earnings investment picks
FREMONT, Calif., Nov.
Sign-up for Identiv to Hold Q3 2014 Earnings Webcast and Conference Call on November 13, 2014 investment picks
FREMONT, Calif., Dec.
Sign-up for Identiv to Present at Imperial Capital's Security Investor Conference investment picks
CAMBRIDGE, Mass., Dec.
Sign-up for Idera Announces Several Key Additions to Management Team investment picks
Toll-like receptor antagonism designed to treat muscle inflammation central to disease progression New approach offers potential to treat broad population of patients regardless of their genetic mutation CAMBRIDGE, Mass.
Sign-up for Idera Pharmaceuticals and Parent Project Muscular Dystrophy Announce Collaboration to Advance New Treatment Approach for Duchenne Muscular Dystrophy investment picks
- IND application for Phase 1 clinical trial of IMO-9200 in healthy volunteers accepted by FDA; patient dosing on track to begin in fourth quarter CAMBRIDGE, Mass., Oct.
Sign-up for Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 investment picks
-- Appointment brings commercial, operational and financial expertise CAMBRIDGE, Mass., Dec.
Sign-up for Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer investment picks
- Clinical safety data for IMO-8400 support dose escalation in ongoing Phase 1/2 trials CAMBRIDGE, Mass., Dec.
Sign-up for Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting investment picks
-- Enrollment achieved in first two dose cohorts of Phase 1/2 Waldenstrom's trial -- Myositis program advanced with specification of Phase 2 clinical trial plan in dermatomyositis --
Sign-up for Idera Pharmaceuticals Reports Third Quarter Financial Results and Announces Expansion of Rare Disease Development Portfolio investment picks
CAMBRIDGE, Mass., Dec.
Sign-up for Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference investment picks
CAMBRIDGE, Mass., Nov.
Sign-up for Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference investment picks
- FDA grants Orphan Drug Designation for IMO-8400 for the treatment of Waldenström's macroglobulinemia - Four-week safety review by Data Review Committee for second dose cohort completed in ongoing WM trial; Third dose cohort opened for enrollment CAMBRIDGE, Mass., Dec.
Sign-up for Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia investment picks
CAMBRIDGE, Mass.
Sign-up for Idera to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
IDEX CORPORATION (NYSE:IEX) today announced its Board of Directors has approved an additional share repurchase authorization of up to $400 million of IDEX’s outstanding common shares.
Sign-up for IDEX Corporation Announces Additional Share Repurchase Authorization investment picks
IDEX CORPORATION (NYSE:IEX) today announced that its Board of Directors has approved a regular quarterly cash dividend of $0.28 per common share.
Sign-up for IDEX Corporation Declares Regular Quarterly Cash Dividend investment picks
IDEX CORPORATION (NYSE: IEX) announced today that it has scheduled the broadcast of the company’s fourth quarter earnings conference call over the Internet on Thursday, January 29th at 9:30 a.m. CT.
Sign-up for IDEX Corporation to Webcast Fourth Quarter 2014 Earnings Call investment picks
IDEXX continues to build upon its highly innovative test menu, expanding veterinarians' medical capability and supporting long-term growth in IDEXX recurring diagnostic revenues WESTBROOK, Maine , Jan.
Sign-up for IDEXX Announces SDMA as Important Expansion to Reference Lab Test Menu investment picks
-- Fourth quarter placements of Catalyst® and premium hematology analyzers in total increased 21% --
Sign-up for IDEXX Instrument Placement Momentum Reinforces Strong Organic Revenue Growth Outlook investment picks
- Delivers 11% normalized organic revenue growth and $1.05 Adjusted EPS, driven by strong growth in all business segments and regions including 12% normalized organic growth in CAG Diagnostics recurring revenues - Catalyst® and hematology instrument placements both increased over 30% in US and international markets - Transition to all-direct sales strategy in the US on track for 100% direct order and fulfillment capability in Q4 - Company announces launch of Catalyst One™, the Company's next generation chemistry analyzer, with customer shipments beginning November 3 - Strong business momentum supports increase in 2014 Adjusted EPS guidance to $3.85 to $3.90 and preliminary 2015 outlook for 13% to 14% normalized organic revenue growth and $4.38 to $4.48 Adjusted EPS WESTBROOK, Maine , Oct.
Sign-up for IDEXX Laboratories Announces Third Quarter Results investment picks
WESTBROOK, Maine , Jan.
Sign-up for IDEXX Laboratories to Present at J.P. Morgan Healthcare Conference investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Identiv CEO Jason Hart to Present at CARTES SECURE CONNEXIONS on Establishing Trust in the Connected World to IDEXX Laboratories, Inc. (Nasdaq: IDXX) to Ring The Nasdaq Stock Market Closing Bell
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent